CY1119576T1 - Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες - Google Patents
Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχεςInfo
- Publication number
- CY1119576T1 CY1119576T1 CY20171101172T CY171101172T CY1119576T1 CY 1119576 T1 CY1119576 T1 CY 1119576T1 CY 20171101172 T CY20171101172 T CY 20171101172T CY 171101172 T CY171101172 T CY 171101172T CY 1119576 T1 CY1119576 T1 CY 1119576T1
- Authority
- CY
- Cyprus
- Prior art keywords
- substituted
- optimes
- triazolo
- dihydro
- acyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η παρούσα εφεύρεση αφορά καινοφανείς ενώσεις του Τύπου (Ι) και τη χρήση τους σε θεραπευτικές αγωγές.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13161863 | 2013-03-29 | ||
EP13193025 | 2013-11-15 | ||
EP14154303 | 2014-02-07 | ||
PCT/EP2014/056367 WO2014154895A1 (en) | 2013-03-29 | 2014-03-28 | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
EP14713844.0A EP2948455B1 (en) | 2013-03-29 | 2014-03-28 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119576T1 true CY1119576T1 (el) | 2018-03-07 |
Family
ID=50391185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171101172T CY1119576T1 (el) | 2013-03-29 | 2017-11-08 | Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες |
Country Status (27)
Country | Link |
---|---|
US (3) | US9422299B2 (el) |
EP (2) | EP3219715A1 (el) |
JP (2) | JP6316932B2 (el) |
KR (2) | KR102218621B1 (el) |
CN (1) | CN105229008B (el) |
AU (1) | AU2014242906B2 (el) |
BR (1) | BR112015024907B1 (el) |
CA (1) | CA2907809C (el) |
CY (1) | CY1119576T1 (el) |
DK (1) | DK2948455T5 (el) |
EA (1) | EA027570B1 (el) |
ES (1) | ES2646488T3 (el) |
HK (2) | HK1214816A1 (el) |
HR (1) | HRP20171688T1 (el) |
HU (1) | HUE035870T2 (el) |
IL (1) | IL241473B (el) |
LT (1) | LT2948455T (el) |
MX (1) | MX370000B (el) |
NO (1) | NO2948455T3 (el) |
NZ (1) | NZ712802A (el) |
PL (1) | PL2948455T3 (el) |
PT (1) | PT2948455T (el) |
RS (1) | RS56501B1 (el) |
SG (1) | SG11201508005XA (el) |
SI (1) | SI2948455T1 (el) |
WO (1) | WO2014154895A1 (el) |
ZA (1) | ZA201506234B (el) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2552920T1 (sl) | 2010-04-02 | 2017-07-31 | Ogeda Sa | Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah |
EA029340B1 (ru) | 2011-10-03 | 2018-03-30 | Огеда Са | ХИРАЛЬНЫЕ N-АЦИЛ-5,6,7,(8-ЗАМЕЩЕННЫЕ)-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПРИМЕНЕНИЯ ПРИ НАРУШЕНИЯХ, ОПОСРЕДОВАННЫХ NK-3 РЕЦЕПТОРАМИ, И ИХ ХИРАЛЬНЫЙ СИНТЕЗ |
JP6275241B2 (ja) | 2013-03-29 | 2018-02-07 | オゲダ エス.エー. | 選択的NK−3受容体拮抗薬としての新規なN−アシル−(3位置換)−5,6,7,8−テトラヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジン、その医薬組成物、NK−3受容体媒介性障害で使用する方法 |
CA2907809C (en) * | 2013-03-29 | 2021-05-04 | Euroscreen Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
US10183948B2 (en) | 2013-03-29 | 2019-01-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
AU2014242908B2 (en) | 2013-03-29 | 2018-07-19 | Ogeda Sa | Novel N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
MX367633B (es) | 2014-09-25 | 2019-08-29 | Ogeda S A | Nueva sintesis quiral de n-acil-(3-sustituidas)-(8-sustituidas)-5, 6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas. |
JP6762312B2 (ja) | 2015-03-16 | 2020-09-30 | オゲダ エス.エー. | 過剰な体脂肪の治療処置または美容処置のためのnk−3受容体拮抗薬 |
KR102122470B1 (ko) * | 2016-12-08 | 2020-06-12 | 주식회사 엘지화학 | 변성제 및 이로부터 유래된 작용기를 포함하는 변성 공액디엔계 중합체 |
EP3428168A1 (en) | 2017-07-12 | 2019-01-16 | Ogeda Sa | Deuterated fezolinetant |
JP2021014404A (ja) * | 2017-10-13 | 2021-02-12 | アステラス製薬株式会社 | トリアゾロピラジン誘導体の塩及び結晶 |
JP2020050814A (ja) * | 2018-09-28 | 2020-04-02 | 住友ベークライト株式会社 | フェノール変性リグニン樹脂を含む樹脂材料、それを用いたフェノール変性リグニン樹脂組成物および構造体 |
IL284159B1 (en) | 2018-12-21 | 2024-04-01 | Ogeda Sa | Synthesis of 3-methyl-4,2,1-thiadiazole-5-carboxyhydrazide or derivatives of its form deuterium methyl-d3 |
CN112272670B (zh) * | 2019-04-16 | 2023-12-12 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
CN113527307A (zh) * | 2020-04-20 | 2021-10-22 | 上海翰森生物医药科技有限公司 | 含***基的并环类衍生物抑制剂、其制备方法和应用 |
CN113549074A (zh) * | 2020-04-26 | 2021-10-26 | 上海翰森生物医药科技有限公司 | 含***基的并环类衍生物抑制剂、其制备方法和应用 |
WO2022022680A1 (zh) | 2020-07-30 | 2022-02-03 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
EP4192834A1 (en) | 2020-08-04 | 2023-06-14 | Teva Pharmaceuticals International GmbH | Solid state forms of fezolinetant and salts thereof |
CN115990164A (zh) * | 2021-10-18 | 2023-04-21 | 武汉大学 | 速激肽受体3抑制剂的用途 |
WO2023138681A1 (zh) * | 2022-01-24 | 2023-07-27 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用 |
WO2024083150A1 (zh) * | 2022-10-19 | 2024-04-25 | 长春金赛药业有限责任公司 | 一种nk3r拮抗剂的晶型及其制备方法和应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000043008A1 (en) | 1999-01-25 | 2000-07-27 | Smithkline Beecham Corporation | Anti-androgens and methods for treating disease |
DE60316416T2 (de) | 2002-03-25 | 2008-06-26 | Merck & Co., Inc. | Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes |
MY139563A (en) | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
EP1628948A1 (de) | 2003-05-21 | 2006-03-01 | Bayer CropScience AG | Difluormethylbenzanilide und deren verwendung zur bekämpfung von mikroorganismen, sowie zwischenprodukte und deren herstellung |
MY152888A (en) | 2004-02-18 | 2014-11-28 | Astrazeneca Ab | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists. |
GB0509405D0 (en) | 2005-05-10 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
SE528833C2 (sv) | 2005-07-29 | 2007-02-27 | Metso Paper Inc | System och metod för att behandla cellulosamassa i samband med utmatning från en satskokare |
GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
WO2010125102A1 (en) * | 2009-04-29 | 2010-11-04 | Glaxo Group Limited | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS |
GB0907515D0 (en) | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
SI2552920T1 (sl) | 2010-04-02 | 2017-07-31 | Ogeda Sa | Nove nk-3 receptor selektivne antagonist spojine, farmacevtski sestavki in postopki za uporabo pri nk-3 receptor posredovanih motnjah |
US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
EA029340B1 (ru) | 2011-10-03 | 2018-03-30 | Огеда Са | ХИРАЛЬНЫЕ N-АЦИЛ-5,6,7,(8-ЗАМЕЩЕННЫЕ)-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПРИМЕНЕНИЯ ПРИ НАРУШЕНИЯХ, ОПОСРЕДОВАННЫХ NK-3 РЕЦЕПТОРАМИ, И ИХ ХИРАЛЬНЫЙ СИНТЕЗ |
CA2907809C (en) | 2013-03-29 | 2021-05-04 | Euroscreen Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
AU2014242908B2 (en) | 2013-03-29 | 2018-07-19 | Ogeda Sa | Novel N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
MX367633B (es) | 2014-09-25 | 2019-08-29 | Ogeda S A | Nueva sintesis quiral de n-acil-(3-sustituidas)-(8-sustituidas)-5, 6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas. |
-
2014
- 2014-03-28 CA CA2907809A patent/CA2907809C/en active Active
- 2014-03-28 LT LTEP14713844.0T patent/LT2948455T/lt unknown
- 2014-03-28 MX MX2015013711A patent/MX370000B/es active IP Right Grant
- 2014-03-28 NZ NZ712802A patent/NZ712802A/en unknown
- 2014-03-28 PT PT147138440T patent/PT2948455T/pt unknown
- 2014-03-28 WO PCT/EP2014/056367 patent/WO2014154895A1/en active Application Filing
- 2014-03-28 RS RS20171128A patent/RS56501B1/sr unknown
- 2014-03-28 JP JP2016504705A patent/JP6316932B2/ja active Active
- 2014-03-28 EP EP17165576.4A patent/EP3219715A1/en not_active Withdrawn
- 2014-03-28 KR KR1020157031249A patent/KR102218621B1/ko active IP Right Grant
- 2014-03-28 KR KR1020217004563A patent/KR102364835B1/ko active IP Right Grant
- 2014-03-28 BR BR112015024907-8A patent/BR112015024907B1/pt active IP Right Grant
- 2014-03-28 SG SG11201508005XA patent/SG11201508005XA/en unknown
- 2014-03-28 CN CN201480018469.6A patent/CN105229008B/zh active Active
- 2014-03-28 EP EP14713844.0A patent/EP2948455B1/en active Active
- 2014-03-28 HU HUE14713844A patent/HUE035870T2/hu unknown
- 2014-03-28 SI SI201430451T patent/SI2948455T1/sl unknown
- 2014-03-28 NO NO14713844A patent/NO2948455T3/no unknown
- 2014-03-28 ES ES14713844.0T patent/ES2646488T3/es active Active
- 2014-03-28 EA EA201591689A patent/EA027570B1/ru unknown
- 2014-03-28 DK DK14713844.0T patent/DK2948455T5/en active
- 2014-03-28 AU AU2014242906A patent/AU2014242906B2/en active Active
- 2014-03-28 PL PL14713844T patent/PL2948455T3/pl unknown
-
2015
- 2015-04-23 US US14/694,228 patent/US9422299B2/en active Active
- 2015-08-26 ZA ZA2015/06234A patent/ZA201506234B/en unknown
- 2015-09-10 IL IL241473A patent/IL241473B/en active IP Right Grant
-
2016
- 2016-03-09 HK HK16102739.4A patent/HK1214816A1/zh unknown
- 2016-03-09 HK HK18103649.9A patent/HK1244273A1/zh unknown
- 2016-07-08 US US15/205,304 patent/US10030025B2/en active Active
- 2016-12-07 US US15/371,600 patent/US9987274B2/en active Active
-
2017
- 2017-11-06 HR HRP20171688TT patent/HRP20171688T1/hr unknown
- 2017-11-08 CY CY20171101172T patent/CY1119576T1/el unknown
-
2018
- 2018-03-28 JP JP2018062649A patent/JP2018118988A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119576T1 (el) | Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες | |
CY1124061T1 (el) | Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες | |
CY1125436T1 (el) | Αναστολεις dna-pk | |
CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
CY1123631T1 (el) | Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr | |
CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
EA201691164A1 (ru) | Производные пиразоло[1,5-a]пиридина и способы их применения | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
EA201492216A1 (ru) | Ингибиторы бромодомена и их применение | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
EA202090291A2 (ru) | Производные бипиразола в качестве ингибиторов jak | |
EA201690746A1 (ru) | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии | |
EA202090371A1 (ru) | 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET | |
BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
EA201992712A2 (ru) | Трициклические гетероциклы как ингибиторы белков бэт | |
EA201591908A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы | |
EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
CL2013002177A1 (es) | Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos. | |
CR20160076A (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA | |
EA201300871A1 (ru) | ПРОИЗВОДНЫЕ (1,2,4)ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ | |
EA201592203A1 (ru) | Способы лечения таупатии | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
CR20150426A (es) | 2,3-benzodiazepinas biciclo y espirocíclico sustituidas |